Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
McKinsey
Boehringer Ingelheim
Chubb
Harvard Business School
Colorcon
Chinese Patent Office
Moodys

Generated: April 26, 2018

DrugPatentWatch Database Preview

PYLERA Drug Profile

« Back to Dashboard

When do Pylera patents expire, and what generic alternatives are available?

Pylera is a drug marketed by Allergan Sales Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in PYLERA is bismuth subcitrate potassium; metronidazole; tetracycline. There are twenty-one drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bismuth subcitrate potassium; metronidazole; tetracycline profile page.

US Patents and Regulatory Information for PYLERA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PYLERA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PYLERA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 140 mg/125 mg/ 125 mg ➤ Subscribe 2014-08-12

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Argus Health
Chubb
US Department of Justice
Colorcon
McKesson
Queensland Health
Daiichi Sankyo
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.